Agile Therapeutics EPS - Earnings per Share 2013-2023 | AGRX
Agile Therapeutics eps - earnings per share from 2013 to 2023. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Agile Therapeutics Annual EPS |
2022 |
$-59.00 |
2021 |
$-1,464.00 |
2020 |
$-1,220.00 |
2019 |
$-760.00 |
2018 |
$-1,160.00 |
2017 |
$-1,820.00 |
2016 |
$-2,040.00 |
2015 |
$-2,760.00 |
2014 |
$-2,820.00 |
2013 |
$-578,780.00 |
2012 |
$-1,207,560.00 |
Agile Therapeutics Quarterly EPS |
2023-09-30 |
$-0.27 |
2023-06-30 |
$-2.15 |
2023-03-31 |
$-5.91 |
2022-12-31 |
$172.98 |
2022-09-30 |
$-8.01 |
2022-06-30 |
$-57.29 |
2022-03-31 |
$-166.68 |
2021-12-31 |
$-1,024.00 |
2021-09-30 |
$360.00 |
2021-06-30 |
$-400.00 |
2021-03-31 |
$-400.00 |
2020-12-31 |
$-420.00 |
2020-09-30 |
$-360.00 |
2020-06-30 |
$-240.00 |
2020-03-31 |
$-200.00 |
2019-12-31 |
$-180.00 |
2019-09-30 |
$-160.00 |
2019-06-30 |
$-160.00 |
2019-03-31 |
$-260.00 |
2018-12-31 |
$-220.00 |
2018-09-30 |
$-220.00 |
2018-06-30 |
$-320.00 |
2018-03-31 |
$-400.00 |
2017-12-31 |
$-340.00 |
2017-09-30 |
$-440.00 |
2017-06-30 |
$-520.00 |
2017-03-31 |
$-520.00 |
2016-12-31 |
$-380.00 |
2016-09-30 |
$-540.00 |
2016-06-30 |
$-580.00 |
2016-03-31 |
$-540.00 |
2015-12-31 |
$-360.00 |
2015-09-30 |
$-840.00 |
2015-06-30 |
$-760.00 |
2015-03-31 |
$-800.00 |
2014-12-31 |
$-1,240.00 |
2014-09-30 |
$-680.00 |
2014-06-30 |
$-920.00 |
2014-03-31 |
$20.00 |
2013-12-31 |
$0.00 |
2013-09-30 |
$-143,340.00 |
2013-06-30 |
$-140,580.00 |
2012-12-31 |
$0.00 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.001B |
$0.011B |
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
|